SN BioScience Secures FDA Orphan Drug Designation for Nanoparticle Cancer Drug SNB-101 in Gastric Cancer
核心洞察
SN BioScience (搜索) received FDA Orphan Drug Designation for SNB-101 in gastric cancer (搜索) on December 10, marking the third orphan designation for this novel nanoparticle formulation of SN-38.
SNB-101 represents the world's first nanoparticle anticancer drug formulating extremely insoluble SN-38 into polymer nanoparticles, designed to improve therapeutic efficacy and reduce side effects.
The designation addresses a significant unmet medical need in gastric cancer (搜索), which has a 5-year survival rate of only 36% and limited treatment options for advanced disease.
South Korean biotech company SN BioScience (搜索) announced that the FDA granted Orphan Drug Designation (ODD) on December 10 for SNB-101 in gastric cancer (搜索), including gastroesophageal junction cancer (搜索). This marks the third orphan designation for the company's lead nanoparticle anticancer drug, following previous designations for small cell lung cancer (搜索) in July 2023 and pancreatic cancer (搜索) in February 2024.
Novel Nanoparticle Formulation Addresses Solubility Challenge
SNB-101 is positioned as the world's first nanoparticle anticancer drug that has formulated extremely insoluble SN-38 into polymer nanoparticles. The drug utilizes a delivery system designed via dual nano-micelle technology, which represents SN BioScience (搜索)'s core platform technology. SN-38 is an active metabolite of irinotecan that is gaining attention for its use in antibody-drug conjugates such as Enhertu® and Trodelvy®.
According to the company, SNB-101 is expected to significantly improve therapeutic efficacy and reduce side effects compared to existing irinotecan products, with improvements in drug resistance and safety profiles demonstrated in preclinical studies.
Addressing Unmet Need in Gastric Cancer
Gastric cancer (搜索) is classified as an extremely rare disease in the United States with a prevalence of less than 200,000 patients and carries a 5-year relative survival rate of only about 36% across all stages. The current standard of care for advanced gastric cancer includes cytotoxic chemotherapy such as irinotecan and paclitaxel, along with targeted therapies like trastuzumab for HER2-positive patients.
However, the prognosis for patients with advanced stages remains poor, with many patients eventually developing resistance to first-line treatments or experiencing disease progression, leaving them with limited effective therapeutic options. In gastric cancer (搜索) animal models, SNB-101 demonstrated excellent efficacy compared to existing standard of care treatments including paclitaxel, irinotecan, and trastuzumab, according to SN Bioscience (搜索).
Clinical Development Progress
SNB-101 has successfully completed Phase 1 clinical trials in patients with solid tumors (搜索) (NCT04640480) and received IND approval for Phase 1b/2 trials from the US FDA in December 2024 for the treatment of small cell lung cancer (搜索). The drug is currently undergoing active clinical development for various solid tumor indications across Korea, Europe, and the United States.
A regulatory protocol review is currently underway in Europe for Phase 2 trials, which will evaluate both monotherapy and combination therapy approaches in patients with small cell lung cancer (搜索).
Regulatory Benefits and Strategic Impact
The orphan drug designation provides SN BioScience (搜索) with several regulatory advantages, including exclusive marketing rights for seven years from the date of approval, tax credits for R&D costs, assistance with clinical trial design, exemption from review application fees, and priority review support.
With this third orphan designation for gastric cancer (搜索), SN BioScience (搜索) expects to gain momentum in indication expansion and clinical development. The company, established in May 2017, specializes in drug delivery systems for anticancer drugs and was founded by pharmaceutical R&D experts, bio-polymer research professors, and clinical professors, focusing on commercialization from its inception.
The company has been developing nanoliposomes and nanoparticle drug carriers based on pharmacometrics and pharmacokinetics, with SNB-101 representing a significant advancement in addressing the formulation challenges associated with SN-38's poor solubility profile.